VBL gene therapy for ovarian cancer shows the future.

Although ovarian cancer is relatively rare, it still has a large number of patients.
recently found that new treatments for PARP inhibitors in people with BRCA variants have found less than satisfactory speed.
Angiogenesics is a speed-limiting step in tumor tissue construction, and it has long been found that if tumors are too small even with a lot of cell mutations, tumor tissue cannot be formed, so Folkman suggested as early as the 1970s that inhibiting angiogenesics is an anti-tumor strategy.
angiogenesy requires the involvement of a large number of cytokines, of which VEGF is the most famous angiogenesic target.
anti-VEGF antibody beva monoantigen is an overweight pound drug, several small molecules VEGFR inhibitors are also good drugs.
but many angiogenesic targets are not clinically effective, such as DLL4-based dual resistance.
the production and stability of protein drugs at other targets, which also limits development.
gene therapy can avoid protein production problems, there are other advantages.
of course, gene therapy also has many technical obstacles, such as expression level, continuity and so on.
immunogenicity is a problem if persistence is poor and the treatment requires repeated dosing.
VB-111 is a complex gene therapy that carries an intrinsic part of the apoptosis Fas gene and an extracellular and trans-membrane part of a TNF-subject gene, carried by the non-replicated Ad5 virus used in yesterday's Russian vaccine.
the vector system is not tissue selective and infects many tissues.
but the therapy has a tissue-specific starter that activates the expression of the carried gene only in oxygen-deprived vascular corted cells.
has been shown in previous years that even Fas mRNA-derived miRNAs have broad-spectrum anti-tumor activity and may be a mechanism for the immune system to remove residual cells before they appear.
if activating this path through the Fas (also known as CD95) lithosome is too toxic because normal liver tissue expresses many lids, it is relatively safe to activate the intracellal Fas segment through the TNF subject.
Now the biopharmaceutical design is becoming more complex, two days ago saw another gene therapy CV301 contain a virus as an immune response supplement, carrying two tumor-specific antigens (CEA, MUC-1), plus three co-exciting molecules (B7-1, ICAM-1, LFA-3).
not only does CAR-T's relatively well-understood technique contain multiple artificially designed parts, but many mechanism-complex therapies also contain multiple unclinically verified ingredients, such as Huang Xinxiang's six-part immunotherapy.
of course a single part does not necessarily mean a single mechanism, the current mechanism of the role of yew alcohol is not very clear.
the traditional saying is to inhibit silk division, but later studies have shown that yew alcohol has little effect on silk division at effective doses.
other tumors are highly heterogeneic and may have different responses from each cell to a particular therapy.
a study this year showed that yew alcohol kills only some of the cells inside the tumor, but when they die, they release IFN and TNF, which induce the death of other tumors.
another study showed that IFNs released by tumors can activate APC to activate T-cells and use the immune system to control tumor growth.
according to such a complex process, it is difficult to reverse the design and finally point to a single set of yew alcohol, clever work only in God not involved in the industry is possible.
.